• Refine Your Search

Contact us

I want to:

Proposal Form

Step 1: Download ACTC Forms

Prior to submitting the form, kindly download forms and complete the required information.

Step 2: Submit to the ACTC Program Administrator

Testemonial Grid

I’m glad I decided to work with ACTC. Their expertise and knowledge about ADRD research is unbeatable.
Bob Ross
Access to ACTC’s wide network of member sites and participating sites ensured that my research was done at the highest level. I’m happy to be a part of ACTC.
Aretha Franklin

Committees

Steering Committee
Chairs:
Learn more
Site Process Improvement, Networking, and Support Committee
Chairs:
Learn more
Site Metrics and Study Budgets Committee
Chairs:
Learn more
Project Evaluation Committee
Chairs:
Learn more
Non-Pharmacological Intervention Committee
Chairs:
Learn more
Non-AD Dementia Committee
Chairs:
Learn more
Neuropsychiatric Symptoms Committee
Chairs:
Learn more
Internal Ethics Committee
Chairs:
Learn more
Executive Committee
Chairs:
Learn more
Early-Career Project Evaluation Committee
Chairs:
Learn more

Units

Recruitment, Engagement, and Retention Unit
Lead:
Co-Associate Leads:
Learn more
PET Unit
Lead:
Co-Associate Leads:
Learn more
Neuropathology Unit
Lead:
Co-Associate Leads:
Learn more
MRI Unit
Lead:
Co-Associate Leads:
Learn more
Medical Safety Unit
Lead:
Co-Associate Leads:
Learn more
Informatics Unit
Lead:
Co-Associate Leads:
Learn more
Inclusion, Diversity, and Education in Alzheimer’s disease Clinical Trials (IDEA-CT) Unit
Lead:
Co-Associate Leads:
Learn more
Clinical Outcome Instruments Unit
Lead:
Co-Associate Leads:
Learn more
Biostatistics Unit
Lead:
Co-Associate Leads:
Learn more
Biomarkers Unit
Lead:
Co-Associate Leads:
Learn more

Member Site Map

[put_wpgm id=2]

Trial Populations

Buttons

Submit ProposalSubmit ProposalSubmit Proposal
Submit Proposal
Read more

Cards

Efficient
Through centralization of resources and processes, we develop and utilize efficient solutions.
Innovative
We lead the field in novel clinical trial designs, leveraging innovative cognitive, biomarker, neuroimaging outcomes, and data sharing.
Inclusive
Our Inclusion, Diversity and Education in Alzheimer’s Disease – Clinical Trials & Inclusive Recruitment committees promote inclusion and diversity in all ACTC activities.
Experienced
Our investigators and sites have the most experience conducting and enrolling ADRD clinical trials.
Collaborative
With each Project’s lead investigator, we build a strong collaborative team to design and conduct trials.

Typography

I am a heading

I am a heading

I am a heading

I am a heading

I am a heading
I am a heading

Body Text - Inter 18px/24lh
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore

Body Text - Inter 16px/24lh
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore

Body Text - Inter 14px/24lh
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore

Body Text - Inter 12px/24lh
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore

Colors

Hero Section

Contact

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus non pulvinar est, sit amet laoreet felis. Nullam ut gravida neque, quis maximus nisl.

Accordion

  • Are proposals required to utilize all 38 Member Sites?

    Yes, the NIA strongly endorses the idea of public private partnerships and ACTC projects can be with academic investigators, biotech companies, small companies, or with Big Pharma through a public private partnership. We want to partner with the community for pharmacological interventions from different sized companies, and different sized academic sites.

  • Does ACTC consider pharmacological interventions?

    Yes, the NIA strongly endorses the idea of public private partnerships and ACTC projects can be with academic investigators, biotech companies, small companies, or with Big Pharma through a public private partnership. We want to partner with the community for pharmacological interventions from different sized companies, and different sized academic sites.

  • How long is the review and feedback process?

    Content goes here ..

  • Is a letter of intent due before the grant deadline?

    Content goes here ..

  • Question nb #2 There are many variations of passages of Lorem Ipsum?

    Content goes here ..

  • Question nb #2 There are many variations of passages of Lorem Ipsum?

    Content goes here ..

  • Question nb #2 There are many variations of passages of Lorem Ipsum?

    Content goes here ..

  • Question nb #2 There are many variations of passages of Lorem Ipsum?

    Content goes here ..

  • Question nb #2 There are many variations of passages of Lorem Ipsum?

    Content goes here ..

  • Question nb #2 There are many variations of passages of Lorem Ipsum?

    Content goes here ..

  • Question nb #2 There are many variations of passages of Lorem Ipsum?

    Content goes here ..

  • Question nb #2 There are many variations of passages of Lorem Ipsum?

    Content goes here ..

Counter card

Sites

0

Trials

0

Publications

0

+

Data Shared

xx

Projects

Landmark Alzheimer’s Data Now Available to Researchers Worldwide
Read more

Your Research Partner

Once a project is funded and approved, ACTC continues to provide ongoing support. We help with study optimizations, training, and safety and our extensive network ensures a broader sample size and diversity of participants for your study.

Ensure Feasibility

We work with you to develop the best study protocols and ensure feasibility, and give you the best chance of funding.

Join the Consortium

We are always looking for new sites and institutes to join us and become part of the ACTC network. 

Allison Hall,

Anthony Caggiano,

MD, PhD

Alison Belsha,

Angelica Forero,

Steering Committee

About:
The Steering Committee is composed of the principal investigators from each of the 38 ACTC Member Sites and the leads from each of the ACTC Units. The committee provides guidance on the management of ACTC, selects projects to be developed into grants, and guides study conduct.

Site Process Improvement, Networking, and Support Committee

Co-Chairs:
Brielle Schreiter
Angelica Forero
Members:
Jaimie Ziolkowski
Sara Mason
BA, BSN, RN
Amelia Troutman
Martha Combs
MS
Molly Harper
Leslie Dunn
Susan Salem-Spencer
Shirley Sirivong
Tia Hall
Carolyn Liebsack
Susie Sami
Roma Patel
Karen Gagnon
Amy Boegel
PhD
Alison Belsha
About:
Recognizing that Site Research Managers and Study Coordinators are a critical component of AD clinical trial infrastructure, and that these roles require a special set of skills and need for support and training, this committee aims to improve infrastructure for AD clinical trials by providing support and mentorship through networking opportunities and providing feedback to ACTC leadership on how to best support training and career development. The committee also aims to improve site processes and study implementation through identifying and disseminating best practices for site and coordinating center processes.

Site Metrics and Study Budgets Committee

Co-Chairs:
Suzanne Craft
PhD
Jonathan Graff-Radford
MD
Members:
Mary Sano
PhD
Martha Combs
MS
Kelly McCann
Thomas Obisesan
MD, MPH
Susie Sami
Alison Belsha
About:
The Site Metrics and Study Budget Committee is responsible for advising ACTC on measures of site performance (enrollment, screen failure rates, retention) and assisting ACTC in determining appropriate budgetary allocations for protocol activities. The committee aims to develop and implement a system of metrics for evaluating site performance, including standardized requirements for becoming an ACTC Member Site and standards for retaining ACTC membership and infrastructure support.

Project Evaluation Committee

Co-Chairs:
Christopher van Dyck
MD
Suzanne Craft
PhD
Members:
Jonathan Graff-Radford
MD
Paul Rosenberg
MD
Gregory Jicha
MD, PhD
Oscar Lopez
MD, FAAN
Po-Heng Tsai
MD
Stephen Salloway
MD
Laurie Ryan
PhD
Bradley Hyman
MD, PhD
About:
The Project Evaluation Committee performs preliminary evaluation of proposals submitted to ACTC for scientific merit, feasibility, and appropriateness. The committee votes on which proposals should be referred to the ACTC Steering Committee and prepares written feedback for proposers.

Non-Pharmacological Intervention Committee

Co-Chairs:
Laura Baker
PhD
Bruno Vellas
MD, PhD
Members:
Jeffrey Burns
MD, MS
Thomas Obisesan
MD, MPH
About:
The Non-Pharmacological Committee provides expertise and guidance in the development and management of ACTC projects involving non-pharmacological approaches in clinical trials, focusing on physical exercise, cognitive/social stimulation, diet/nutrition, and other exposures proposed to impact AD risk or trajectory (sleep, light, toxins, etc). The committee also encourages and facilitates the standardization of methods used to deliver and assess success of non-pharmacological interventions to support harmonization and data sharing across studies.

Non-AD Dementia Committee

Co-Chairs:
Bradley Boeve
MD
Adam Boxer
MD, PhD
Members:
Jonathan Graff-Radford
MD
Sharon Sha
MD, MS
Charles Bernick
MD, MPH
Lisa Silbert
MD, MCR
About:
The Non-AD Dementia Committee advises on trial design for ACTC projects with a non-AD population.

Neuropsychiatric Symptoms Committee

Chair:
Jeffrey Cummings
MD, ScD
Members:
Anton Porsteinsson
MD
Brigid Reynolds
MSN, ANP-BC
Elaine Peskind
MD
Oscar Lopez
MD, FAAN
Paul Rosenberg
MD
Danielle Goldfarb
MD
Pierre Tariot
MD
About:
The Neuropsychiatric Symptoms Committee advises leadership on trial design for studies of agents, devices, or non-pharmacologic interventions targeting neuropsychiatric symptoms such as agitation, psychosis, depression, apathy, and sleep disorders. The committee also assists in designing trials for non-AD dementia such as frontotemporal dementia and dementia with Lewy bodies where behavioral symptoms are prominent, and encourages companies and others with psychotropic drugs to approach ACTC for review and possible trial conduct.

Internal Ethics Committee

Co-Chairs:
Joshua Grill
PhD
Jason Karlawish
MD
Members:
Judith Heidebrink
MD
Jonathan Graff-Radford
MD
Milap Nowrangi
MD, MBe
Gregory Jicha
MD, PhD
Seth Gale
MD
Charles Bernick
MD, MPH
Emily Largent
PhD, RN
About:
The Internal Ethics Committee monitors and manages the financial relationships (industry ties and intellectual property holdings) of individuals who have a role in protocol selection, development, and analyses; this includes unit leads, and members of the Project Feasibility Committee, Early-Career Project Evaluation Committee, Project Evaluation Committee, and Steering Committee. The committee develops policies to address these relationships and provides ACTC investigators, staff, and collaborators with ethics education and consultation.

Executive Committee

Members:
Alesia Cole
MSN, RN, APNP, ACRP-CP
Amanda Smith
MD
Anton Porsteinsson
MD
Christopher van Dyck
MD
Clifford Jack
MD
Dorene Rentz
Dorene Rentz
PsyD
Gregory Jicha
MD, PhD
Gustavo Jimenez-Maggiora
PhD, MBA
Jeremy Pizzola
Joshua Grill
PhD
Keith Johnson
MD
Laurie Ryan
PhD
Matthew Frosch
MD, PhD
Michael Donohue
PhD
Michael Rafii
MD, PhD
Michael Weiner
MD
Paul Aisen
MD
Reisa Sperling
MD, MMSc
Rema Raman
PhD
Robert Rissman
PhD
Ronald Petersen
MD, PhD
Sharon Sha
MD, MS
Suzanne Craft
PhD
Vijay Ramanan
MD, PhD
About:
The Executive Committee is responsible for overseeing ACTC and advising leadership on key decisions. The committee reviews consortium governance and communications issues, and reviews the progress of ongoing ACTC clinical trials and discusses any challenges as they arise.

Early-Career Project Evaluation Committee

Chair:
Ram Bishnoi
MD
Vice Chair:
Adam Mecca
MD, PhD
IDEA-CT Unit Liaison:
Athene Lee
PhD
Members:
Kirsten Wright
ND, MCR, MS
Kyra O’Brien
MD
Elif Pinar Coskun
MD
Gregg Day
MD
Irina Skylar-Scott
MD
Parichita Choudhury
Patricia Andrews
MD
Mentors:
Karen Bell
MD
Neelum Aggarwal
MD
Gad Marshall
MD
Paul Newhouse
MD
About:
The Early-Career Project Evaluation Committee is a committee under the Inclusion, Diversity and Education in Alzheimer’s disease – Clinical Trials (IDEA-CT) Unit, charged with enhancing the training of early-career investigators in protocol review and development by providing a platform to contribute in the evaluation and selection of ACTC projects.

Recruitment, Engagement, and Retention Unit

Co-Leads:
Joshua Grill
PhD
Rema Raman
PhD
Co-Associate Leads:
Crystal Glover
PhD
Doris Molina-Henry
PhD
About:
The Recruitment, Engagement, and Retention (RER) Unit aims to accelerate participant accrual, enhance participant demographic diversity, and maximize retention in ACTC clinical trials using culturally cognizant, data-driven, and evidence-based strategies. The unit also engages in the science of recruitment to expand the available evidence and to develop methodologically rigorous approaches to improve trial recruitment outcomes. The primary aims of the unit are (1) to provide RER leadership in designing trials that are feasible and can successfully enroll inclusive samples, (2) to develop and sustain engagement and collaborations among study sites and community-based researchers with established partnerships and trust in underrepresented communities, and (3) to develop and utilize an evidence base to instruct clinical trial recruitment and retention approaches and resource expenditures, and to widely disseminate learnings to the field.

PET Unit

Lead:
Keith Johnson
MD
About:
The PET Unit provides a comprehensive set of services that address all aspects of PET needed for ACTC programs including: designing protocols tailored to a proposed study design (project-specific use of amyloid PET for inclusion/exclusion and outcome assessment, and use of Tau PET, FDG, or other tracers for outcome assessments), and implementing these protocols at sites.

Neuropathology Unit

Co-Leads:
Matthew Frosch
MD, PhD
Gregory Jicha
MD, PhD
About:
The Neuropathology Unit captures the critical information available from autopsy examination of clinical trial subjects, in order to: confirm pathologic diagnosis, define endophenotypes, elucidate the biological action of the treatment (including both on and off-target effects that may underlie adverse events), unravel multifactorial contributions to the clinical state (including comorbid pathologies that may alter the response to the intervention), and bank tissue for future investigations.

MRI Unit

Co-Leads:
Michael Weiner
MD
Clifford Jack
MD
About:
The MRI Unit provides a comprehensive set of services that address all aspects of MRI needed for clinical trials including: designing imaging acquisition protocols tailored to any proposed study design, implementing protocols on all vendor systems needed for any given trial, site qualification, updating protocols when systems are upgraded, ongoing monitoring and image quality control, and implementing image analysis methods that address needs of any proposed study.

Medical Safety Unit

Lead:
Michael Rafii
MD, PhD
About:
The Medical Safety Unit provides oversight to the safety and conduct of ACTC’s entire portfolio of clinical trials. This is accomplished through medical and safety monitoring, clinical site monitoring, coding and review of adverse events, review of protocol deviations, and responding to medical questions from sites regarding study conduct. The ultimate goal of the unit is to ensure the safety of all participants in ACTC clinical trials and to develop better methods for clinical trials safety monitoring.

Informatics Unit

Lead:
Gustavo Jimenez-Maggiora
PhD, MBA
About:
The Informatics Unit is composed of two groups: Data Management and Informatics. The unit develops and maintains the ACTC Informatics Platform (ACTC-IP) to support ACTC and its scientific aims. The ACTC-IP serves as an extensible, secure, and scalable information, collaboration, and process management infrastructure to facilitate the effective execution of program and study-related research activities by ACTC units, investigators, study teams, and sites. The ACTC-IP provides facilities to collect, store, process, analyze, visualize, audit, and share scientific, operational, and administrative data using standardized data models, formats, and taxonomies.

Inclusion, Diversity, and Education in Alzheimer’s disease Clinical Trials (IDEA-CT) Unit

Co-Leads:
Rema Raman
PhD
Reisa Sperling
MD, MMSc
Training and Mentoring Lead:
Dorene Rentz
Dorene Rentz
PsyD
Emerging Leaders Representative:
Athene Lee
PhD
Internal Advisory Board Co-Chairs:
Neelum Aggarwal
MD
Amanda Smith
MD
About:
The Inclusion, Diversity and Education in Alzheimer’s disease – Clinical Trials (IDEA-CT) Unit aims to create an equitable and inclusive environment within ACTC activities through inculcating Justice, Equity, Diversity, and Inclusion (JEDI) principles across the consortium culture, strategy, and processes. These principles will establish the framework to identify, train, and sponsor a well-trained and diverse workforce and leadership to design, execute, and lead the next generation of ACTC clinical trials. The primary objectives of the unit are (1) to establish an ACTC strategic plan based on a JEDI leadership model, (2) expand existing networking, training, and education programs to support ACTC clinical trials staff, early and mid-career investigators, and emerging leaders, and (3) create opportunities for advancement for the next generation of leaders for ACTC.

Clinical Outcome Instruments Unit

Co-Leads:
Ronald Petersen
MD, PhD
Dorene Rentz
Dorene Rentz
PsyD
About:
The Clinical Outcome Instrument Unit brings extensive experience in designing and implementing novel tools to assess cognitive function across the continuum. The unit in addition provides oversight and guidance to the quality of cognitive assessment in ACTC programs. This effort includes training and certification of raters and audio recording of all primary outcome assessments with central review and performance feedback.

Biostatistics Unit

Co-Leads:
Rema Raman
PhD
Michael Donohue
PhD
About:
The Biostatistics Unit aims to advance clinical trials of Alzheimer’s and related dementias (ADRD) through the utilization and development of innovative trial design, a comprehensive quality assurance program, and state-of-the-art statistical methodologies and analytic approaches. These approaches allow the rapid start-up of trials, real-time monitoring of data quality, sophisticated statistical analysis, and effective sharing of archived data. The primary aims of the unit are to (1) provide statistical leadership in the design, conduct, and analysis of ACTC projects; (2) ensure the integrity, rigor, and reproducibility of study results; and (3) conduct innovative statistical research in ADRD.

Biomarkers Unit

Lead:
Robert Rissman
PhD
About:
The Biomarkers Unit manages the Biorepository at the ACTC Coordinating Center as well as the distributed efforts on assay optimization for early stage trials at several member sites. The key objective of the unit is to provide the infrastructure necessary for storage, pharmacokinetics screening, and optimization of tools for preventive studies.